Literature DB >> 17908403

Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist.

T G Lainas1, I A Sfontouris, I Z Zorzovilis, G K Petsas, G T Lainas, E M Kolibianakis.   

Abstract

Several approaches have been proposed for the management of OHSS that reduce, but do not completely eliminate the incidence of human chorionic gonadotrophin (HCG)-induced early severe OHSS. Three women diagnosed with polycystic ovarian syndrome underwent ovarian stimulation for IVF using a gonadotrophin-releasing hormone (GnRH) antagonist protocol. Three days after oocyte retrieval, severe early OHSS was diagnosed by analysis of haematocrit (Ht), white blood cell (WBC) count, serum urea, and ultrasonographic assessment of ovarian size and ascitic fluid. On the same day, antagonist administration was re-initiated and continued daily for a week, while all embryos were cryopreserved. No progression of severe early OHSS was observed in any of the patients. A marked decrease of Ht, WBC count, ovarian volume and ascitic fluid was observed during 1 week of follow-up, and none of the patients required hospitalization. GnRH antagonist re-initiation might represent a new strategy for flexible management of patients with established severe early OHSS. Based on the flexibility of the approach, if severe OHSS does not occur, patients may proceed to embryo transfer, while if severe early OHSS ensues, antagonist administration combined with embryo cryopreservation appear to be associated with prevention of life-threatening OHSS, facilitation of regression of severe OHSS to a moderate form and avoidance of patient hospitalization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908403     DOI: 10.1016/s1472-6483(10)60366-5

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  15 in total

1.  GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.

Authors:  Yannis Prapas; Konstantinos Ravanos; Stamatios Petousis; Yannis Panagiotidis; Achilleas Papatheodorou; Chrysoula Margioula-Siarkou; Assunta Iuliano; Giuseppe Gullo; Nikos Prapas
Journal:  J Assist Reprod Genet       Date:  2017-08-03       Impact factor: 3.412

2.  What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study.

Authors:  Theoni B Tarlatzi; Christos A Venetis; Fabienne Devreker; Yvon Englert; Anne Delbaere
Journal:  J Assist Reprod Genet       Date:  2017-07-14       Impact factor: 3.412

3.  Abdominal Compartment Syndrome Due to OHSS.

Authors:  Firoozeh Veisi; Maryam Zangeneh; Shohreh Malekkhosravi; Negin Rezavand
Journal:  J Obstet Gynaecol India       Date:  2013-09-28

4.  A unique human chorionic gonadotropin antagonist suppresses ovarian hyperstimulation syndrome in rats.

Authors:  Pratibhasri A Vardhana; Martin A Julius; Susan V Pollak; Evan G Lustbader; Rhonda K Trousdale; Joyce W Lustbader
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

5.  GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Ivy Maina; Clarisa Gracia; Anuja Dokras
Journal:  J Assist Reprod Genet       Date:  2016-06-27       Impact factor: 3.412

6.  Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?

Authors:  Ya-Qin Wang; Jin Luo; Wang-Min Xu; Qin-Zhen Xie; Wen-Jie Yan; Geng-Xiang Wu; Jin Yang
Journal:  J Ovarian Res       Date:  2015-09-23       Impact factor: 4.234

7.  Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.

Authors:  George T Lainas; Efstratios M Kolibianakis; Ioannis A Sfontouris; Ioannis Z Zorzovilis; George K Petsas; Theoni B Tarlatzi; Basil C Tarlatzis; Trifon G Lainas
Journal:  Reprod Biol Endocrinol       Date:  2012-08-31       Impact factor: 5.211

8.  GnRH analogues in the prevention of ovarian hyperstimulation syndrome.

Authors:  Pilar Alama; Jose Bellver; Carmen Vidal; Juan Giles
Journal:  Int J Endocrinol Metab       Date:  2013-04-01

9.  Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis.

Authors:  Nalini Mahajan; Shalu Gupta; Shilpa Sharma; Kumkum Rani; Padmaja Naidu; Puneet R Arora
Journal:  J Hum Reprod Sci       Date:  2015 Oct-Dec

Review 10.  Optimal usage of the GnRH antagonists: a review of the literature.

Authors:  Alan B Copperman; Claudio Benadiva
Journal:  Reprod Biol Endocrinol       Date:  2013-03-15       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.